CRISPR Therapeutics Seals Global Deal

CRISPR Therapeutics, Intellia Therapeutics (NTLA), Caribou Biosciences, and ERS Genomics said Friday that they together with their licensors entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.

The parties to the agreement include the co-owners of the intellectual property — the Regents of the University of California, Emmanuelle Charpentier, and the University of Vienna — as well as key licensees and sublicensees — CRISPR Therapeutics, ERS Genomics, Caribou Biosciences, and Intellia Therapeutics.

Under the agreement, the parties commit to maintain and coordinate the prosecution, defense and enforcement of the CRISPR/Cas9 foundational patent portfolio worldwide, and each of the co-owners of the intellectual property grants cross-consents to all existing and future licenses and sublicenses based on the rights of another co-owner.

By Marvin Goff